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AbstrAct
The Prevention of Adult Caries Study, an NIDCR-
funded multicenter, double-blind, randomized clinical 
trial, enrolled 983 adults (aged 18-80 yrs) at high risk for 
developing caries (20 or more intact teeth and 2 or more 
lesions at screening) to test the efficacy of a chlorhexi-
dine diacetate 10% weight per volume (w/v) dental coat-
ing (CHX). We excluded participants for whom the 
study treatment was contraindicated or whose health 
might affect outcomes or ability to complete the study. 
Participants were randomly assigned to receive either 
the CHX coating (n = 490) or a placebo control (n = 
493). Coatings were applied weekly for 4 weeks and a 
fifth time 6 months later. The primary outcome (total net 
D1-2FS increment) was the sum of weighted counts of 
changes in tooth surface status over 13 months. We 
observed no significant difference between the two treat-
ment arms in either the intention-to-treat or per-protocol 
analyses. Analysis of 3 protocol-specified secondary 
outcomes produced similar findings. This trial failed to 
find that 10% (w/v) chlorhexidine diacetate coating was 
superior to placebo coating for the prevention of new car-
ies (Clinicaltrials.gov registration number NCT00357877).
KEY WOrDs: caries, chlorhexidine coating, RCT-
Randomized Clinical Trial,  adults, prevention.
IntrODuctIOn
Despite the high prevalence and impact of dental caries among adults, pre-vention research has focused primarily on children (Griffin et al., 2005), 
and strategies to prevent adult caries have remained essentially unchanged 
for many years. Prescription strength or over-the-counter fluoride products 
are recommended for adults with high caries risk but have not been suffi-
cient to reduce caries (Featherstone, 2008). An NIDCR consensus confer-
ence (Horowitz, 2004) emphasized the need to expand the evidence base for 
preventive agents for adults and suggested that chlorhexidine, an antimicrobial 
agent, merited further consideration. A 13-month trial in 240 45- to 75-year-old 
xerostomic individuals with high S. mutans counts tested the caries-preventive 
effects of 3 treatments: CHX dental coating (chlorhexidine diacetate 10% 
weight per volume [w/v] , Prevora®); a placebo coating (benzoin sumatra USP 
20% [w/v]); and a sham coating (Banting et al., 2000). CHX Technologies, 
Inc. (Toronto, ON, Canada) supplied all the coatings. In the intention-to-treat 
analysis, the active treatment group had 40.8% fewer root surfaces with caries 
(p ≤ 0.02) and 14.4% fewer coronal surfaces with caries (p ≤ 0.06) relative to 
the placebo coating group. No significant difference was seen versus the sham 
coating control group.
This paper reports the primary findings of a trial testing the same agent in 
a larger, more diverse population of adults.
MAtErIAls & MEthODs
The Prevention of Adult Caries Study (PACS) was a multicenter, placebo-
controlled, double blind, randomized clinical trial designed to test the hypoth-
esis that a CHX coating, compared with a placebo coating, reduces dental 
caries increment in at-risk adults over a period of 13 mos. The study was 
conducted under an Investigational New Drug license from the US Food and 
Drug Administration (FDA).
The detailed study rationale and design are described elsewhere (Vollmer 
et al., 2010). Summary details are provided here and in the Appendix. Four 
clinical centers provided a diverse sample with respect to fluoride exposure, 
dental reimbursement, and race: Delta Dental (Westborough, MA, USA); 
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Kaiser Permanente Dental Program (Portland, OR, USA); Tuba 
City Regional Health Care Corporation (Navajo Nation in 
Arizona, USA); and Tufts University School of Dental Medicine 
(Boston, MA, USA). The study chair was at Tufts; Kaiser 
Permanente Center for Health Research in Portland, OR, served 
as the data coordinating center. The Institutional Review Board 
at each institution approved the study, all participants provided 
written informed consent, and all study personnel were trained 
and certified in Good Clinical Practice (Food and Drug 
Administration, 1996).
study Population
Participants were from 18 to 80 yrs old and had 20 or more 
intact teeth and 2 or more lesions (at least 1 cavitated) at screen-
ing. We excluded participants for whom the study treatment was 
contraindicated or whose health might affect outcomes or ability 
to complete the study.
Sites used a variety of means to identify likely eligible 
individuals, who were then invited for a formal eligibility 
screening visit. Before participants were randomized, they 
received restorative care for all cavitated lesions from a dentist 
who was independent of the study. A second, baseline oral 
examination was obtained at the randomization visit, after 
which the initial treatment was applied. Of 1521 individuals 
attending an initial screening visit, 124 (8%) were ineligible, 
983 (65%) were randomized, and the remainder either refused 
or were still pending at the close of recruitment (Fig.).
randomization and blinding
Participants and staff were blinded to study arm. A centralized 
Web-based application randomized participants 1:1 to receive 
CHX or its placebo. Randomization was stratified by clinical 
center and age tertiles with permuted blocks of various sizes 
within strata. Staff received a number corresponding to a sealed 
box containing the treatment vials for that participant. Active 
and placebo materials were packaged identically by an indepen-
dent vendor, and were distinguishable only by a numeric label.
study treatments
Study treatments were applied by blinded and certified person-
nel after participants received a rubber cup prophylaxis with 
non-fluoridated paste and gross scaling as needed. The first 4 
treatment applications occurred weekly in the first mo after 
randomization, followed by a fifth treatment 6 mos later. 
Cavitated lesions discovered at the fifth visit were restored 
before the coatings were applied. Participants received either the 
active coating (chlorhexidine diacetate 10% [w/v], Sumatra 
benzoin 20% [w/v], and alcohol, Prevora®) or the placebo coat-
ing (Sumatra benzoin 20% [w/v] and alcohol), followed by 
application of a methacrylate coating designed to protect the 
initial coating. CHX Technologies, Inc. (Toronto, ON, Canada) 
supplied all the coatings. Coatings were applied to all tooth 
surfaces, and staff weighed each vial before and after applica-
tion to assess the applied dose. We did not attempt to assess 
whether material was left on the applicator or lost to evaporation. 
Although the active and placebo coatings had some differences 
in taste, this was not noticeable when the materials were applied 
according to protocol. A detailed rationale for the treatment 
protocol is included in the Appendix.
schedule and types of Measurements
Demographic information and predictors of caries were collected 
at initial screening. Medical history, oral health behaviors, and 
caries data were collected at randomization and again 7 and 13 
mos post-randomization. Information about medical history 
changes, soft tissue changes, adverse events, medication usage, 
and acidic beverage consumption was collected at each visit. 
Adverse events were coded by certified coordinating center staff 
using the Medical Dictionary for Regulatory Activities (MedDRA 
Maintenance and Support Services Organization, 2005).
caries Examination
Paralleling previous trials of the same agent (Banting et al., 
2000; Forgie et al., 2000), we used the Pitts & Fyffe taxonomy 
(Pitts and Fyffe, 1988), which identifies 3 stages of lesions on 
Figure. Flowchart for participants in the PACS trial.
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coronal surfaces: non-cavitated lesions (D1); cavitation extend-
ing into, but not through, the enamel (D2); and cavitated lesions 
that involve the dentin (D3). The classification was extended to 
root surfaces with 2 stages: non-cavitated (D1) and cavitated 
(D2). Caries was judged visually (without radiographs) by 
trained, calibrated examiners using proper lighting, 5 sec of air-
drying, and a CPITN probe. Examiners also noted missing teeth 
(M), unscorable surfaces (Y), and the presence of crowns (C) or 
fillings (F) on tooth surfaces; for example, a code of CD1 
denoted the presence of both a crown and a marginal D1 lesion 
on a surface. Pit and fissure sealants were coded but treated as 
sound (S) surfaces in our analysis. We also treated D2 and D3 
lesions equivalently and refer to them hereafter as simply D2 
lesions. Calls for all 32 possible teeth were recorded, and all 
teeth were judged to have 9 surfaces (5 coronal and 4 root), 
making a total of 288 surface calls.
Examiners received calibration training annually (Banting 
et al., 2011). Unweighted kappa (Cohen, 1960) was used to 
estimate intra- and inter-examiner reliability of the 5×5 classi-
fication of sound vs. D1 vs. D2 vs. filled or crowned vs. missing 
or unscorable. Aggregating over calibration sessions and exam-
iners, the mean intra- and inter-examiner reliabilities were 0.86 
and 0.77 (see Appendix for more extensive calibration results).
Outcome Measures
The primary outcome (total net D1-2FS increment) was the sum 
of weighted counts of transitions in tooth surface status (root 
and coronal surfaces combined) from randomization to the 
13-month follow-up visit. Disease progression had a positive 
weight (e.g., S-to-D1 or D1-to-D2 = 1, S-to-D2 = 2). Reversal had 
a negative weight (e.g., D1-to-S = −1). No change, transitions to 
or from missing or unscorable, and impossible transitions had 0 
weight. Incident fillings and crowns were treated the same as 
incident D2 lesions for purposes of scoring.
Three secondary outcomes were examined: the cumulative 
net D1-2FS increment (which was similar to the total net D1-2FS 
increment but separately scored and combined transitions from 
the baseline to 7-month visit and from the 7- to 13-month visits), 
the total crude D1-2FS increment (analogous to the total net 
D1-2FS increment but ignoring reversals), and the cumulative 
crude D1-2FS increment (analogous to the cumulative net D1-2FS 
increment but ignoring reversals). All scores were rank-normalized 
and re-scaled to observed mean and variance over all partici-
pants (Banting et al., 2000).
statistical Analysis
The primary outcome analysis (conducted with SAS® Release 
9.2) was performed on the Intention-to-Treat sample (ITT) with 
standard linear regression, with treatment and site as class vari-
ables and age and age-squared as continuous covariates. A 
planned secondary analysis tested for a site-by-treatment inter-
action. Identical analyses were carried out in the per-protocol 
subsample (defined as participants receiving all 5 treatments 
and with data collected on a protocol-defined schedule) and for 
all 3 secondary outcomes in both samples. No interim analysis 
was conducted.
We used SAS® PROC MI to create 8 imputed datasets via 
data augmentation with Markov Chain Monte Carlo sampling 
(Schafer and Graham, 2002). Identical analyses were run on each 
dataset, with results combined with SAS® PROC MIANALYZE 
to obtain p-values that were adjusted for the uncertainty inherent 
in imputing missing data (Rubin, 1987). The statistician was 
blinded to treatment group in the 13-month data until after the 
imputations were completed and data were locked.
Sample size was estimated with simulated data with rank nor-
malized scores. We calculated that 832 participants would yield a 
power of 90% to detect a 20% reduction in caries incidence (from 
a hypothesized mean increment of 1.5), and adopted a target of 
1000 randomized participants to allow for attrition.
Participants who had one or more treatment applications 
were included in the safety analysis, which computed odds 
ratios and 90% confidence intervals for adverse events reported 
by 1% or more of the participants based on the MedDRA® 
Preferred Term classification.
rEsults
The two study arms were well-matched by baseline characteris-
tics (Table 1). Follow-up and treatment adherence were excel-
lent (Fig.). The mean dose of CHX over all applications in the 
ITT sample was 41 mg (95% CI = 40.1, 41.5 mg), with mean 
cumulative dose of 198.4 mg (95% CI = 194.7, 202.0 mg). The 
corresponding target doses were 33 mg/application and 165 mg 
cumulative.
The vast majority (94%) of “transitions” between the baseline 
and 13-month visits were no change (diagonals in Appendix Table 
6). Ignoring the impossible transitions, which are not scored in the 
analysis, the mean number of cavitated, filled, or crowned tooth 
surfaces increased from 31.8 to 34.1 per participant over this 
timeframe, while the mean number of surfaces with uncavitated 
(D1) lesions decreased from 7.1 to 4.2. Since 93% of root surfaces 
were not exposed, these represent primarily coronal data.
For the ITT sample, we failed to observe a significant differ-
ence in total net D1-2FS increment between the two treatment 
arms, with the observed increment actually higher for the active 
group (Table 2). No significant site-by-treatment interaction was 
observed (p = 0.49), although there was a significant site main 
effect (p < 0.0001). Analyses of secondary outcomes for the ITT 
sample and of all 4 outcomes in the per-protocol sample pro-
duced qualitatively similar results (Table 3).
In the safety sample, the incidence of adverse events differed 
for only 2 events. Pharmaceutical product complaint (e.g., 
unpleasant taste) was higher in the active group (28 vs. 12 par-
ticipants, OR = 2.4, 90% CI = 1.4, 4.3), while dyspepsia was 
reported more frequently among those in the placebo arm (9 vs. 
2, OR = 0.2, 90% CI = 0.1, 0.8). To our knowledge, no one 
became unblinded as a result of the taste of the coatings.
Unplanned exploratory analysis of the net D2FS caries incre-
ment (i.e., treating D1 lesions as sound) found no overall treat-
ment effect (see Appendix).
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DIscussIOn
The PACS study has numerous important strengths, including 
the randomized design, double-blind treatments, careful atten-
tion to quality control, excellent participant retention and proto-
col adherence, a large sample, and generalizability to populations 
with varied dental delivery systems, access to dental care, and 
levels of fluoride exposure.
Our negative findings might have several explanations. First, 
the 10% (w/v) CHX coating used in this study may not be effica-
cious for coronal caries prevention. Consistent with our results, 
Banting and co-workers (Banting et al., 2000) did not see a 
table 1. Baseline Characteristics of Randomized Participants
Active Placebo Overall
 (n = 490) (n = 493) (n = 983)
Age (yrs)a 42.9 (14.3) 42.8 (14.3) 42.8 (14.3)
Age range (min, max) 18, 78 18, 80 18, 80
Male (%) 49.2 50.7 49.9
Hispanic ethnicityb (%) 6.9 6.7 6.8
Race (%)
 American Indian/Alaska Native 18.0 16.2 17.1
 Asian/Native Hawaiian/Other Pacific Islander 2.7 4.5 3.6
 African American 5.5 6.5 6.0
 Caucasian 69.8 69.6 69.7
 More than one race/Other 3.1 2.6 2.9
 Don’t know/Refused 1.0 0.6 0.8
Income c (%)
 Less than $30,000 16.8 17.3 17.0
 $30,001 to $50,000 19.0 17.1 18.0
 $50,001 to $75,000 21.4 22.0 21.7
 Over $75,000 29.3 30.0 29.7
 Don’t know 7.4 7.3 7.4
 Refused 6.2 6.3 6.3
Total number of cavitated surfacesa 2.8 (2.9) 3.0 (3.0) 2.9 (2.9)
Total number of D1 surfacesa 6.9 (7.0) 7.6 (8.1) 7.2 (7.5)
D1MFS score (across all 288 possible surfaces)a,b 86.9 (37.3) 87.1 (34.8) 87.0 (36.0)
aContinuous data presented as mean (standard deviation).
bIncludes imputed data.
cData not available for Tuba City, n = 816 overall, 406 active arm, 410 placebo arm.
table 2. Adjusted Mean Combined Coronal and Root Net D1-2FS Increment Scores in the Intent-to-Treat Sample, by Treatment Arm and by Site, 
with Results of Tests of Main Effects of Treatment and Site
Treatment Arm Mean SE 95% Conf. Interval p-value
Active (n = 490) 2.68 0.32 (2.05, 3.30)  
Placebo (n = 493) 2.43 0.32 (1.80, 3.05)  
Active − Placebo 0.25 0.44 (−0.60, 1.11) 0.56
 p-values for Site Differences
Site Mean SE Delta Portland Tuba City
Delta (n = 180) 3.31 0.52  
Portland (n = 403) 0.50 0.35 < 0.0001  
Tuba City (n = 167) 1.25 0.53 0.0056 0.24  
Tufts (n = 233) 5.15 0.45 0.0074 < 0.0001 < 0.0001
Group means computed by the SAS LSMEANS procedure adjusted for treatment, site, age, and age-squared. Site effects are mean scores across 
treatment arms and not site-specific treatment differences. Treatment effect and all p-values derived from corresponding linear regression 
model. Outcome includes imputed data.
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statistically significant effect on coronal caries for chlorhexidine 
vs. either the placebo-coating or sham control groups. Similarly, 
Forgie and colleagues (Forgie et al., 2000) found no greater effect 
of a chlorhexidine coating on D1-2 increment than in a placebo 
control in a three-year study of 1240 adolescents, although adher-
ence in that study was poor. Systematic reviews have also found 
the evidence for chlorhexidine to be weak, especially for coronal 
caries prevention and in patients who are not at very high risk of 
caries progression (James et al., 2010; Bekhuis, 2011; Slot et al., 
2011). Since PACS participants had very few exposed root sur-
faces, ours was a study of primarily coronal caries increment.
Second, PACS included transitions to and from uncavitated 
(i.e., D1) lesions in the primary outcome. We chose this outcome 
based on ICDAS reports and on assertions of sensitivity and 
efficiency of the D1 outcome from other research (Kingman and 
Selwitz, 1997; Chesters et al., 2002; Biesbrock and Bartizek, 
2005). Nonetheless, we acknowledge that D1 lesions are more 
difficult to detect than D2 lesions, especially when they are 
located interproximally just under the contact.
Third, it may be that our follow-up period was too short for 
an effect to be observed, but this seems unlikely, given that the 
estimated overall treatment effect in this study, though essen-
tially zero, was in the opposite direction from that predicted. 
Moreover, we had greater power than originally planned to 
detect a 20% drop in mean caries increment, since the observed 
caries increment in the placebo group was higher than assumed 
in our sample size calculations (2.4 vs. 1.5).
Other factors may also have contributed to our negative find-
ings. Participants had all cavitated lesions restored at baseline 
and again midway through the study, and had a rubber cup pro-
phylaxis and gross scaling as needed prior to each treatment 
application. These factors, together with the fact that a protec-
tive coating was applied at each treatment visit, may have 
reduced the cariogenic microflora in all participants (Axelsson 
et al., 2004). Certainly the decrease in D1 surfaces that occurred 
in participants in both treatment arms suggests that remineral-
ization was achieved in both groups, though the lack of a prophy 
cleaning at the final examination could also have impaired 
visibility and thus contributed to an increase in missed D1 calls 
at that visit. In addition, participants had varying use of fluoride 
products (including the fluoridated toothpaste provided by the 
study) and varying exposure to fluoridated community water. 
While this may have improved the generalizability of our find-
ings, it may also have inflated the variance of our study out-
comes. Finally, lack of radiographs (done at the request of the 
FDA) may have reduced the accuracy of the calls made during 
the oral examinations.
This trial of 10% CHX dental coating found no evidence of 
anti-caries effect on the net or crude D1-2FS increment. Based on 
these findings and the available literature, we conclude that 
chlorhexidine is not effective in preventing coronal caries. It 
may have a role in the prevention of root caries in very high-risk 
populations, although further studies would be needed to con-
firm this.
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table 3. Results of Secondary Outcome Analyses
Active Placebo Difference 95% CI p-value
Intention-to-treat sample n = 490 n = 493  
Cumulative net D1-2FS increment   5.88 ± 0.43   5.53 ± 0.42 0.35 ± 0.57 (–0.77, 1.46) 0.54
Total crude D1-2FS increment   5.96 ± 0.28   6.47 ± 0.27 –0.51 ± 0.38 (–1.25, 0.23) 0.18
Cumulative crude D1-2FS Increment 10.72 ± 0.43 11.39 ± 0.42 –0.68 ± 0.57 (–1.80, 0.45) 0.24
Per-protocol sample    n = 382 n = 394  
Total net D1-2FS increment 2.55 ± 0.36   2.51 ± 0.36 0.04 ± 0.49 (–0.92, 0.99) 0.94
Cumulative net D1-2FS increment 5.62 ± 0.45   5.48 ± 0.44 0.14 ± 0.61 (–1.05, 1.33) 0.81
Total crude D1-2FS increment 5.91 ± 0.30   6.51 ± 0.30 –0.60 ± 0.41 (–1.41, 0.21) 0.15
Cumulative crude D1-2FS Increment 10.35 ± 0.45 11.20 ± 0.44 –0.85 ± 0.61 (–2.04, 0.34) 0.16
Group means ± SEs computed by the SAS LSMEANS procedure adjusted for treatment, site, age, and age-squared. Treatment effects and all 
p-values derived from corresponding linear regression model. All outcomes include imputed data.
J Dent Res 91(2) 2012 Efficacy of Chlorhexidine for the Prevention of Adult Caries  155
rEFErEncEs
Axelsson P, Nystrom B, Lindhe J (2004). The long-term effect of a plaque 
control program on tooth mortality, caries and periodontal disease in 
adults. Results after 30 years of maintenance. J Clin Periodontol 
31:749-757.
Banting DW, Papas A, Clark DC, Proskin HM, Schultz M, Perry R (2000). 
The effectiveness of 10% chlorhexidine varnish treatment on dental 
caries incidence in adults with dry mouth. Gerodontology 17:67-76.
Banting DW, Amaechi B, Bader JD, Blanchard P, Gilbert GH, Holland 
JC, et al. (2011). Examiner training and reliability in two randomi- 
zed clinical trials of adult dental caries. J Public Health Dent  
(in press).
Bekhuis T (2011). Chlorhexidine varnish may prevent dental caries in chil-
dren and adolescents. J Evid Based Dent Pract 11:84-86.
Biesbrock AR, Bartizek RD (2005). The Biesbrock-Bartizek Caries Clinical 
Model. In: Clinical Models Workshop: Remin-Demin, Precavitation, 
Caries. Proceedings of the Seventh Indiana Conference, July 3-5, 2005. 
Stookey GK, editor. Indianapolis: Indiana University School of 
Dentistry, pp. 143-160.
Chesters RK, Pitts NB, Matuliene G, Kvedariene A, Huntington E, 
Bendinskaite R, et al. (2002). An abbreviated caries clinical trial design 
validated over 24 months. J Dent Res 81:637-640.
Cohen J (1960). A coefficient of agreement of nominal scales. Psychol Bull 
20:37-46.
Featherstone JD (2008). Dental caries: a dynamic disease process. Aust Dent 
J 53:286-291.
Food and Drug Administration (1996). Guidance for industry E6 good clinical 
practice: consolidated guidance. URL accessed on 8/19/2011 at: http://www 
.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ 
Guidances/UCM073122.pdf
Forgie AH, Paterson M, Pine CM, Pitts NB, Nugent ZJ (2000). A randomised 
controlled trial of the caries-preventive efficacy of a chlorhexidine-contain-
ing varnish in high-caries-risk adolescents. Caries Res 34:432-439.
Griffin SO, Griffin PM, Swann JL, Zlobin N (2005). New coronal caries in 
older adults: implications for prevention. J Dent Res 84:715-720.
Horowitz AM (2004). A report on the NIH Consensus Development 
Conference on Diagnosis and Management of Dental Caries throughout 
Life. J Dent Res 83(Spec Iss C):C15-C17.
James P, Parnell C, Whelton H (2010). The caries-preventive effect of 
chlorhexidine varnish in children and adolescents: a systematic review. 
Caries Res 44:333-340.
Kingman A, Selwitz RH (1997). Proposed methods for improving the effi-
ciency of the DMFS index in assessing initiation and progression of 
dental caries. Community Dent Oral Epidemiol 25:60-68.
MedDRA Maintenance and Support Services Organization (2005). MedDRA - 
the Medical Dictionary for Regulatory Activities. International Federation 
of Pharmaceutical Manufacturers and Associations (IFPMA). URL 
accessed on 8/24/2011 at: http://www.meddramsso.com/index.asp.
Pitts NB, Fyffe HE (1988). The effect of varying diagnostic thresholds upon 
clinical caries data for a low prevalence group. J Dent Res 67:592-596.
Rubin DM (1987). Multiple imputation for nonresponse in surveys. New 
York: John Wiley & Sons.
Schafer JL, Graham JW (2002). Missing data: our view of the state of the 
art. Psychol Methods 7:147-177.
Slot DE, Vaandrager NC, Van Loveren C, Van Palenstein Helderman WH, 
van der Weijden GA (2011). The effect of chlorhexidine varnish on root 
caries: a systematic review. Caries Res 45:162-173.
Vollmer WM, Papas AS, Bader JD, Maupome G, Gullion CM, Hollis JF, 
et al. (2010). Design of the Prevention of Adult Caries Study (PACS): 
a randomized clinical trial assessing the effect of a chlorhexidine dental 
coating for the prevention of adult caries. BMC Oral Health 10:23.
AuthOrs' nOtE
PACS Collaborative Group
Delta Site, Oral Health Center, Westborough, MA, USA
Alex White DDS, DrPH, MS; Peter Blanchard DDS, MBA; Joy-Ann 
Deane DDS; Keith Hamburger RDH; Joanne Johnson RDH; Kristen 
Johnson RDH; Rosemary Marangi-Marsden RDH; Nydia Molina DA; 
Kimberly O’Connor CDA; Joanne Tavano CDA; Gay Torresyap RDH, 
MS, CCRC
Tuba City Site, Tuba City Regional Health Care Corporation, Tuba 
City, AZ, USA
Gerardo Maupome BDS, MSc, PhD; Marilyn Begay; Tracy Goldtooth; 
Jacqueline Haskie; Eric Honanie; Adrinne Masaquaptewa; Junhie Oh 
DDS, MPH; Rantreva Peaches; Kathy Phipps PhD, DDS; L.D. Robertson 
MD, MPH; Shelli Ryczek RDH, BS; Corina Talayumptewa; TCRHCC 
officers and staff; NNHRRB officers and staff 
Tufts Site, Tufts University School of Dental Medicine, Boston, MA, USA
Athena Papas DMD, PhD; Elizabeth Arkema BS; Ashley Brown BS; 
Virginia Burns BS, RDH; Moira Casey BS; Pamela Corrado BS; 
Mark Douglas DH; Kachan Ganda MD; Harish Gulati DMD; Dorothy 
Harrington BS; Lucie Krizova MPH; Karen Lee BS; Julie O’Connor BS, 
DH; Lauren Ragone BS; David Russell DMD, MPH; Medha Singh BDS, 
MS; Mabi Singh BDS, MS; John Cleeve Soter BS DH; George Stevens 
DMD; Shankeertha Sundaralingam BS, MS; Elizabeth Tzavaras DA
Portland Site, Kaiser Permanente Center for Health Research, Portland, 
OR, USA
John Snyder DMD; Diane Bernel RDH; John Brittan DMD; Leah Brooks 
CRSI; Jennifer Carlston CRSII; Paul Cheek; Donna Clark CRSII; Joyce 
Downing; Kelsie Farrell CRSII; Donna Gleason; Janet Hankins RDH; 
Jack Hollis PhD; Cheryl Johnson EdM; Dan LaFerriere RN; Sally Jo 
Little RDH; Lisa Massinger; Kristin Muessig CRSII; Ora Lee Olson 
RDH; Kim Richards CRSI; Craig Snyder DMD; Barbara Strong
Data Coordinating Center, Kaiser Permanente Center for Health 
Research, Portland, OR, USA
William M. Vollmer PhD; James Bader DDS, MPH; Jeanette Bardsley; 
Kristina Booker BS; Chuhe Chen PhD; Ping Chen MS; Arthor Dixon 
MS; Judy Donald MA; Charles Elder MD, MPH; Jeffrey Fellows PhD; 
Kimberly Funkhouser BS; Christina Giullion PhD; Kelly Kirk; Reesa 
Laws BS; Celeste Machen; Gayle Meltesen MS; Sumithran Rasathurai 
PhD; Deborah Reck
